Clinical Research Directory
Browse clinical research sites, groups, and studies.
Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia
Sponsor: Englewood Hospital and Medical Center
Summary
The purpose of this expanded access study is to be able to provide treatment with HBOC-201 to patients with life-threatening anemia for whom blood is not an option. HBOC-201 is not FDA approved for use in the United States, but is approved as an oxygen carrier in South Africa and Russia.
Official title: Expanded Access Protocol for the Treatment Use of HBOC-201
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2013-10
Completion Date
2026-12
Last Updated
2025-04-13
Healthy Volunteers
No
Conditions
Interventions
HBOC-201
HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.
Locations (1)
Englewood Hospital and Medical Center
Englewood, New Jersey, United States